Pulmonary fibrosis represents the end stage of a number of heterogeneous conditions and
is, to a greater or lesser degree, the hallmark of the interstitial lung diseases. It is …

Fibrosis is the concluding pathological outcome and major cause of morbidity and mortality
in a number of common chronic inflammatory, immune-mediated and metabolic diseases …

Idiopathic pulmonary fibrosis (IPF) is a poorly understood disease that usually leads to death
within 5 years of diagnosis. Despite our better understanding of IPF pathogenesis, the …

Idiopathic pulmonary fibrosis (IPF) is a long-lasting, continuously advancing, and irrevocable
interstitial lung disorder with an obscure origin and inadequately comprehended …

Pulmonary fibrosis is a pathologic process associated with scarring of the lung interstitium.
Interstitial lung diseases (ILDs) encompass a large and heterogenous group of disorders, a …

Pulmonary fibrosis is characterized by lung inflammation and abnormal tissue repair,
resulting in the replacement of normal functional tissue with an abnormal accumulation of …

Idiopathic pulmonary fibrosis (IPF) is a chronic progressive disease of unknown cause
characterized by relentless scarring of the lung parenchyma leading to reduced quality of life …

Idiopathic pulmonary fibrosis (IPF) is a progressive, lethal fibrotic lung disease that occurs
primarily in middle-aged and elderly adults. It is a major cause of morbidity and mortality …

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive diffuse parenchymal lung
disease of unknown origin, with a mortality rate exceeding that of many cancers. The …

Idiopathic pulmonary fibrosis (IPF) is a unique type of chronic fibrosing lung disease of
unknown etiology. The sequence of the pathogenic mechanisms is unknown, but the …